A Phase I Study of Weekly Doxorubicin and Oral Topotecan for Patients With Relapsed or Refractory Small Cell Lung Cancer (SCLC).

Trial Profile

A Phase I Study of Weekly Doxorubicin and Oral Topotecan for Patients With Relapsed or Refractory Small Cell Lung Cancer (SCLC).

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2016

At a glance

  • Drugs Doxorubicin (Primary) ; Topotecan (Primary)
  • Indications Small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 15 Jun 2016 The dosage of doxorubicin hydrochloride has been amended; (on day 6 in weeks 1-15) to (day 6 of course 1 and on days 6, 13, and 20 of courses 2-5)
    • 15 Jun 2016 Planned number of patients changed from 18 to 30.
    • 15 Jun 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top